Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsPatient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsChemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaFeasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for huInnate immune regulation by STAT-mediated transcriptional mechanisms.Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factorsClinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.Febrile neutropenia in chemotherapy treated small-cell lung cancer patientsEfficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer.Neutropenia and G-CSF in lymphoproliferative diseases.Real-world impact of granulocyte-colony stimulating factor on febrile neutropeniaBloodstream infections in neutropenic cancer patients: A practical update.Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving ChemotherapyCompatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceImpact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropeniaInterpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Bloodstream infections in patients with solid tumors.Supportive Care in Older Adults with Cancer: Across the Continuum.Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness.Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
P2860
Q24198118-429B81D5-5DC5-4A4D-BDA3-DCDA968E1D24Q26749476-05123278-02B7-49C3-9516-6FF24A978DA4Q27008080-663EC38A-5729-4B78-9823-8754053C4418Q30975418-B289AC45-A28F-4BDE-87F0-3B2E88C06A5DQ33413142-C9915DA5-2CB3-47D5-B4AC-A21670A340CCQ33414659-77EA49B3-B26B-43C6-98A5-458A77074EFEQ33778817-B715DE72-5312-4E1D-AB53-179E52BD454FQ33829742-61A689CB-505E-4B1C-8719-57313E5151DAQ34055968-358C1444-96E3-4EBB-ABB8-0F1F2164D289Q35123683-DA9425C3-F07A-401F-917E-B3139FE51ABFQ35165571-A9DAD47C-5E6B-4828-BE72-8BB2C970542DQ35165579-0EB18E50-91D1-48F5-BB0B-AD7AF863D4BBQ35297079-B607AEEE-9304-4CB4-9AD2-BAB98C8A4800Q35303471-0016BB33-FB58-4016-A9DD-C0DE4AF99872Q35811836-C187D0D1-9FF6-44FF-9DE2-C89E382BE5C3Q36023851-33075FA8-D33D-4FAE-8912-55D7A06099A9Q36672788-D85B85E6-066F-4B0F-8CD2-39F6ECACA412Q36828921-EB4FA550-16D0-40E5-85AC-EAD294C9C41EQ36897773-945812B5-F09F-4A14-9379-EBC1142EFA55Q36913345-73D1CFBF-509E-4D79-9598-0807E74A6E4DQ37072872-F8D4FC52-4FD1-430C-865A-17831E515CA7Q37373201-73D125B5-FE1D-4E89-90AF-CFB63955D837Q37554901-2BF7F7E9-E860-4CC3-8577-654957DACFA3Q37737572-68691AF9-45CF-43B5-9CBB-3852D6E17D0DQ37931905-1C1D9917-BDD5-49BF-A222-41E49DF58BACQ38225700-91B42F0D-0E35-4770-A51B-B69F387AD764Q38253136-6762A113-3F52-4F64-97C7-77318F402368Q38256944-B9A7986C-3757-47C7-8131-A9F4ED223FD2Q38405004-45F02633-95BB-423A-93B6-CBF079FA10DEQ38580333-C1C85804-8E10-4FD1-969B-97C44740A8FBQ38613025-59FBF408-82F9-4000-8C1B-A058B6835A9CQ38626569-A69AEAE7-E7BB-42E7-A65F-C8AFB97DC513Q38682028-C5C5B60B-4F74-4848-9D4B-F322EC479AF4Q38703440-9AE3E352-59E8-4157-A087-43529B655314Q38876363-A9DA818A-2848-4FEC-8165-4A45863877A8Q38940016-CF74E669-8E12-4568-BBAA-31E50EC90222Q40094120-A3E830EB-85BA-4C0B-92C6-E071D9144B93Q40121607-9859C2A8-0DA5-4E53-BC38-1902EE31DE3AQ40156982-6A5F40F9-8DBF-4AF2-BCBE-DFC83C24B11DQ40222201-9C485547-529A-4CFA-85A6-D773FD4EC197
P2860
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@ast
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@en
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@nl
type
label
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@ast
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@en
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@nl
prefLabel
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@ast
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@en
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@nl
P2093
P2860
P356
P1433
P1476
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
@en
P2093
ESMO Guidelines Working Group
J Crawford
P2860
P304
P356
10.1093/ANNONC/MDQ195
P478
21 Suppl 5
P577
2010-05-01T00:00:00Z